United Therapeutics Announces World's First Bioengineered External Liver Treatment in Clinical Study

United Therapeutics Corporation (NASDAQ:UTHR) is one of the most undervalued US stocks according to analysts. On June 24, United Therapeutics Corporation and Intermountain Health announced a medical breakthrough: the world’s first patient treated in a clinical study with a bioengineered external liver assist product called miroliverELAP.

This historic procedure marked the first human clinical trial of a manufactured organ alternative and was performed at Intermountain Medical Center in Murray, Utah, by a team led by Christopher J. Danford, MD, who is a transplant hepatologist at Intermountain Health. The patient treated was experiencing liver failure and was not eligible for a liver transplant.

MiroliverELAP was developed by Miromatrix Medical Inc., which is a subsidiary of United Therapeutics and is an external liver assist combination product. It comprises a single-use MIRO-001 bioengineered liver and an extracorporeal blood circuit, designed to provide temporary liver support for patients with acute liver failure/ALF. ALF is a severe condition characterized by a rapid loss of liver function, often in individuals with no prior history of liver disease.

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally.

While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.